<DOC>
	<DOCNO>NCT02941328</DOCNO>
	<brief_summary>A trial investigate effect pyridostigmine ( mestinon ) versus placebo double-blind cross trial patient hereditary proximal spinal muscular atrophy ( SMA ) type 2 , 3 4 .</brief_summary>
	<brief_title>SPACE Trial : Pyridostigmine v Placebo SMA Types 2 , 3 4</brief_title>
	<detailed_description>In cross-over trial investigate effect pyridostigmine ( mestinon ) versus placebo fatigability patient hereditary proximal spinal muscular atrophy ( SMA ) type 2 , 3 4 ( age 12 old ) The study participant use placebo 8 week mestinon 8 week . Both investigator patient blind treatment allocation period . Patients randomly assign use placebo mestinon first . At end study , patient use mestinon placebo 8 week . In phase ( period ) cross study , study medication dosage slowly increase maximum dosage 6 mg/kg/day ( spread 4 dos daily ) order either prevent side effect manage good possible . This scheme allow u assist participant case side effect occur early . Although strive patient dosage per kg body weight , serious side effect obviously lead lower dosage . Before start medication use ( either placebo pyridostigmine ) , baseline measurement take : physical examination data concern primary secondary outcome ( MFM , MRC score , fatigability test , etc . ) collect . After use drug ( mestinon/placebo ) 8 week test repeat , evaluate possible medication effect . After wash-out period approximately 1-2 week scheme use second study period ( i.e . cross-over design ) . Unblinding follow entire study complete ( i.e . : last included patient finish participation ) .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Spinal Muscular Atrophies Childhood</mesh_term>
	<mesh_term>Pyridostigmine Bromide</mesh_term>
	<criteria>A clinical diagnosis SMA type 2 , 3a , 3b 4 Genetically confirm homozygous SMN1 deletion Ability complete visit trial period ; Given oral write informed consent ≥18 year old ; Given inform consent parent legal representative ( ) case patient age ≥12 till &lt; 18 year old ( accordance Dutch law ) Ability perform least 2 subsequent round Nine Hole Peg test A maximum total Motor Function Measure ( MFM ) score 80 % ( i.e . : maximum score 80 % D1+D2+D3 subscores ) . Known concomitant disorder NMJ ( e.g . limit : Lambert Eaton myasthenic syndrome , myasthenia gravis ) ; Use drug may alter NMJ function Classic SMA type 1 ; Apprehension participation EMG ; Inability meet study visit ; Mechanical gastrointestinal , urinary biliary obstruction ; Clinical significant alteration laboratory test ( electrolyte , liver function , kidney function , thyroid function blood dysplasia ) drawn within 14 day prior start study entry ; ECG abnormalities know contraindication pyridostigmine use ; Current pregnancy breastfeed Allergy bromide Severe bronchial asthma ( case uncertainty diagnosis , contact treat pulmonologist physician ) Total MFM score baseline ( screen ) &gt; 80 % ( i.e . : maximum total MFM score 80 % D1+D2+D3 subscores ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>SMA , SMN1 , Kugelberg-Welander</keyword>
</DOC>